Inovio Pharmaceuticals, Inc.

INO · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.3%

Institutions46.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$65343	$217756	$832010	$10.26M	$1.77M	$7.41M	$4.11M	$30.48M	$2.57M	$340563
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$86.82M	-$112.40M	-$143.94M	-$267.57M	-$301.22M	-$124.08M	-$111.11M	-$94.09M	-$83.64M	-$76.24M
Operating income as a percentage of revenue.	-132871.3%	-51616.9%	-17300.3%	-2607.4%	-16972.3%	-1674.2%	-2702.1%	-308.7%	-3251.6%	-22385.3%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$84.95M	-$107.25M	-$135.10M	$0	$0	-$1.06M	-$119.36M	-$96.97M	-$88.21M	-$73.74M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.81	$-3.95	$-6.00	$-1.00	$-1.45	$-1.07	$-1.00	$-1.00	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.81	$-3.95	$-6.00	$-1.00	$-1.45	–	$-1.00	$-1.00	$-1.00	$-1.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$44.27M	$65.81M	$14.31M	$46.33M	$71.14M	$250.73M	$22.20M	$23.69M	$23.79M	$19.14M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$74.31M	$113.20M	$170.95M	$348.53M	$495.94M	$539.77M	$143.95M	$131.11M	$187.24M	$173.71M
All of the company's interest-bearing borrowings, short and long term combined.	–	$0	$16.77M	–	–	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$50.21M	$44.69M	$53.60M	$126.17M	$96.27M	$78.63M	$138.55M	$44.08M	$44.75M	$50.33M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$24.10M	$68.50M	$117.35M	$222.36M	$399.67M	$461.14M	$3.44M	$86.94M	$142.39M	$123.28M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$88.63M	-$104.08M	-$124.37M	-$216.22M	-$215.71M	-$177.98M	-$97.85M	-$73.55M	-$63.21M	-$62.56M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$285698	$487832	$320898	$969153	$1.23M	$1.52M	$987926	$2.09M	$10.29M	$2.74M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$88.92M	-$104.56M	-$124.69M	-$217.18M	-$216.94M	-$179.50M	-$98.84M	-$75.64M	-$73.50M	-$65.29M

	You	Peer avg
Revenue Growth	–	-32.3%
ROE	-409.9%	-324.0%

Inovio Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison